KR102808320B1 - 사람 세포내 부착 분자 1(icam-1)에 대한 안티센스 약물 - Google Patents

사람 세포내 부착 분자 1(icam-1)에 대한 안티센스 약물 Download PDF

Info

Publication number
KR102808320B1
KR102808320B1 KR1020217026805A KR20217026805A KR102808320B1 KR 102808320 B1 KR102808320 B1 KR 102808320B1 KR 1020217026805 A KR1020217026805 A KR 1020217026805A KR 20217026805 A KR20217026805 A KR 20217026805A KR 102808320 B1 KR102808320 B1 KR 102808320B1
Authority
KR
South Korea
Prior art keywords
antisense oligonucleotide
icam
disease
condition
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217026805A
Other languages
English (en)
Korean (ko)
Other versions
KR20210120034A (ko
Inventor
게오르그 스차키엘
로젤 크레츄머-카체미 파
Original Assignee
우니베지태트 주 뤼벡
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 우니베지태트 주 뤼벡 filed Critical 우니베지태트 주 뤼벡
Publication of KR20210120034A publication Critical patent/KR20210120034A/ko
Application granted granted Critical
Publication of KR102808320B1 publication Critical patent/KR102808320B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020217026805A 2019-01-25 2019-12-17 사람 세포내 부착 분자 1(icam-1)에 대한 안티센스 약물 Active KR102808320B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19153666 2019-01-25
EP19153666.3 2019-01-25
PCT/EP2019/085539 WO2020151881A1 (en) 2019-01-25 2019-12-17 Antisense drug against the human intercellular adhesion molecule 1 (icam-1)

Publications (2)

Publication Number Publication Date
KR20210120034A KR20210120034A (ko) 2021-10-06
KR102808320B1 true KR102808320B1 (ko) 2025-05-15

Family

ID=65234475

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217026805A Active KR102808320B1 (ko) 2019-01-25 2019-12-17 사람 세포내 부착 분자 1(icam-1)에 대한 안티센스 약물

Country Status (6)

Country Link
US (1) US12480128B2 (https=)
EP (1) EP3914710A1 (https=)
JP (1) JP7307505B2 (https=)
KR (1) KR102808320B1 (https=)
CN (1) CN113454220B (https=)
WO (1) WO2020151881A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114525244A (zh) * 2022-02-15 2022-05-24 中南大学 一种牙周牙髓联合病变组织中间充质干细胞的焦亡产物在疾病发生发展中的机制研究方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE236250T1 (de) 1998-09-25 2003-04-15 Deutsches Krebsforsch Antisense-sequenzen für die hemmung der expression des adhäsionsmoleküls icam-1
AU2002256359A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
US7919472B2 (en) * 2004-09-17 2011-04-05 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
US11293064B2 (en) * 2013-05-02 2022-04-05 Thomas Jefferson University Human miRNAs for use in diagnosis, prognosis, and therapy of human conditions and diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Antisense& nucleic acid drug development, Vol.12, pp.71-78 (2002)
Chemistry& Biology, Vol.19(8), pp.937-954 (2012.08.24.)
Nucleic Acids Research, Vol.27(22), pp.4328-4334 (1999.11.01.)

Also Published As

Publication number Publication date
KR20210120034A (ko) 2021-10-06
US20220106601A1 (en) 2022-04-07
WO2020151881A1 (en) 2020-07-30
EP3914710A1 (en) 2021-12-01
JP2022524913A (ja) 2022-05-11
JP7307505B2 (ja) 2023-07-12
CN113454220B (zh) 2024-08-23
US12480128B2 (en) 2025-11-25
CN113454220A (zh) 2021-09-28

Similar Documents

Publication Publication Date Title
AU2019200789B2 (en) Multimeric oligonucleotide compounds
AU2018202634B2 (en) Multimeric oligonucleotide compounds
EP2960333B1 (en) Composition for inhibiting gene expression and uses thereof
EP2438168B1 (en) Polynucleotides for multivalent rna interference, compositions and methods of use thereof
EP3444350B1 (en) Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded rna
EP1444347B1 (en) METHOD FOR THE IN VITRO SYNTHESIS OF SHORT DOUBLE STRANDED RNAs
WO2009046104A1 (en) Aptamer-targeted sirna to prevent attenuation or suppression of t cell function
HK1206387A1 (en) Organic compositions to treat kras-related diseases
KR102808320B1 (ko) 사람 세포내 부착 분자 1(icam-1)에 대한 안티센스 약물
KR102519171B1 (ko) 암 치료를 위한 새로운 접근법
TW201119681A (en) Compositions and methods for inhibiting expression of KIF10 genes
US20220298512A1 (en) Sirna sequences targeting the expression of human genes jak1 or jak3 for a therapeutic use
JP2026510985A (ja) 環状プロドラッグ核酸を使用したｒｎａ治療薬の送達
EP1668144A2 (en) Nucleotide sequences promoting the trans-membrane transport of nucleic acids
CN103597075A (zh) 用于选择性地杀伤细胞的生物活性核苷酸分子、其用途及应用试剂盒
EP1592412A1 (en) Down-regulation of target-gene with pei/single-stranded oligoribonucleotide complexes
EP2689013A1 (en) Compositions for inhibiting gene expression and uses thereof
HK40075388A (en) Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded rna
HK40013196A (en) Multimeric oligonucleotide compounds

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210823

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211208

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231127

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240827

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250417

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250512

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250513

End annual number: 3

Start annual number: 1

PG1601 Publication of registration